Medical dermatology company LEO Pharma A/S reported on Tuesday the completion of the acquisition of the exclusive rights to develop and market brodalumab (marketed as Kyntheum in the EU) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited.
The new sub-licensing agreement includes Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia. This agreement complements the ongoing licensing agreement between the two companies to develop and market brodalumab for moderate-to-severe psoriasis in Europe.
Pursuant to the new arrangement, Bausch Health has awarded LEO Pharma A/S with an exclusive license to its global rights to brodalumab, but continues to hold the rights for the US and Canada.
Outside of the EU, Bausch Health Companies Inc and AstraZeneca have owned the global commercial rights for brodalumab except in Japan and other Asian countries, where the rights are owned by Kyowa Kirin Co Ltd.
Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin. Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person's life.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins